BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3„¢platform technology for the delivery of therapeutics across the blood-brain barrier (the BBB) and the treatment of central nervous system (CNS) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the creation of the Medical Oncology Advisory Board and the appointments of Dr. John DeGroot M.D., Dr. Hope Rugo M.D. and Dr. Javier Corts M.D. PhD. The goals of this board will be to guide the clinical strategy and design of the xB3-001 clinical program for the treatment of HER2+ breast cancer and brain metastases. The Medical Oncology Advisory Board will be chaired by Jos Iglesias, MD, who has been appointed consultant Chief Medical Officer for Bioasis Technologies Inc.
Dr. Jos Iglesias, Chairperson of the Advisory Board in his role of consultant Chief Medical Officer is a biopharmaceutical industry veteran with 30 years of executive experience in all phases of oncology clinical drug development covering the areas of solid tumor oncology, immuno-oncology and translational medicine. His career includes senior positions at Eli Lilly, Amgen, Abraxis Bioscience, Celgene, Bionomics, Biothera, Apobiologix and Boston Biomedical. Dr. Iglesias is author or co-author of more than 60 peer-reviewed publications with over 6,000 literature citations and an active member of ASCO, ESMO and AACR. He graduated from the University of Montevideo, Uruguay, and received additional training at the Weizmann Institute of Science (Rehovot, Israel), Duke University Medical Center (Durham, NC) and the University of Toronto.
I am delighted to welcome Jos to the Bioasis team, strengthening our oncology development expertise at a critical time as we progress our lead program xB3-001 for the treatment of HER2+ breast cancer and brain metastases. I am also extremely pleased to welcome John, Hope and Javier to the Medical Oncology Advisory Board. Each member is a leader in their field with proven track records of excellence in clinical practice and clinical drug development in the areas of breast cancer and CNS oncology. Deborah Rathjen added, Ph.D., Executive Chair of Bioasis. We look forward to continuing to benefit from the strength of the collective experience of our medical board as we advance our xB3 programs toward the clinic.
Dr. Jos Iglesias commented, Treatment of HER2+ breast cancer that has metastasized to the brain remains a significant challenge. To date, xB³-001 has demonstrated highly encouraging preclinical results, and I am excited to be working with Dr. Rathjen and the Bioasis team to continue to advance this class-leading technology.
Dr. John de Groot is a Professor, and Chairman ad interim, in the Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center. He is an expert in the fields of glioma angiogenesis and molecularly targeted therapy. Dr. de Groot has served as the principal investigator (PI) or co-investigator on multiple funded National Cancer Institute, foundation, and industry-sponsored grants. He is the principal investigator of numerous clinical trials involving novel agents being tested in patients with glioblastoma and is a leader of MD Andersons Glioblastoma Moon Shot. Dr. de Groot has over 112 peer reviewed articles. He is or has been a peer reviewer for 23 scientific journals, both national & international, and is on four editorial review boards. He completed his medical education at The University of Texas Medical Branch at Galveston, and pursued internship and residency at The Johns Hopkins School of Medicine.
Dr. Hope S. Rugo is Professor of Medicine at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, where she is also the director of Breast Oncology and Clinical Trials Education. She is a principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer and improving safety with targeted agents and has published widely in this area with over 200 peer reviewed articles. Dr. Rugo is an active member of the Translational Breast Cancer Research Consortium (TBCRC), a principal investigator of several TBCRC trials and is the co-chair of the Triple Negative Working Group. She is a member of the Breast Committee for the Alliance cooperative group, and is an associate editor for the American Society of Clinical Oncology (ASCO) annual meeting educational book. Dr. Rugo graduated from the University of Pennsylvania School of Medicine. She completed a residency in internal medicine followed by a fellowship in hematology and oncology at UCSF as well as a research fellowship at Stanford University.
From June 2003 to July 2015, Dr.Corts worked in the Department of Medical Oncology at the Hospital Vall d’Hebron, Barcelona, where he has been Coordinator of the Teaching and Training Programme for Residents in Oncology and Senior Specialist in the Area of Breast Cancer with a special interest in new drug development. Dr. Corts was the Head of the Breast Cancer Program and the Melanoma Unit from July 2006 to August 2015. From September 2015 to October 2018, he has been Head of the Breast Cancer and Gynecological tumors at Ramon y Cajal University Hospital in Madrid. He is Clinical Investigator of the Breast Cancer Research Program at Vall dHebron Institute of Oncology, and Head of Breast Cancer Program, IOB Institute of Oncology, Madrid and Barcelona, Spain. Dr Corts is the author of more than 240 publications, with a focus on breast tumors and new drugs, and more than 500 communications at multiple conferences. He actively participates in the development of numerous national and international clinical investigations. Dr Corts received a degree in Medicine and Surgery from the Universidad Aut³noma de Madrid with continued studies at the University of Navarra, specializing in Medical Oncology at the Clnica Universitaria de Navarra. In addition to his medical specialties, he has two masters degree in Medical Direction and Clinical Management from the Universidad Nacional de Educaci³n a Distancia (UNED) and Research Methodology in Health Sciences from the Universidad Aut³noma de Barcelona as well as a degree in Statistics in Health Sciences from the same university.
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3„¢platform, a proprietary technology for the delivery of therapeutics across the BBB and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. Bioasis internal pipeline programs are focused on treatments for orphan indications, including certain brain cancers, and rare diseases, including Gauchers Disease Type II. Bioasis trades on the TSX Venture Exchange under the symbol BTI and on the OTCQB under the symbol BIOAF. For more information about the Company, please visit www.bioasis.us.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Follow us on:
- LinkedIn: https://www.linkedin.com/company/bioasis-technologies-inc/
On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Executive Chair of the Board